Cassava Sciences (Cassava Sciences) EBIT per Share : $-2.53 (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Cassava Sciences EBIT per Share?

Cassava Sciences's EBIT per Share for the three months ended in Dec. 2023 was $-0.54. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.53.

During the past 3 years, the average EBIT per Share Growth Rate was -113.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -49.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cassava Sciences's EBIT per Share or its related term are showing as below:

SAVA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -136.3 Med: -4.25 Max: 74.8
Current: -113.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cassava Sciences was 74.80% per year. The lowest was -136.30% per year. And the median was -4.25% per year.

SAVA's 3-Year EBIT Growth Rate is ranked worse than
97.24% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs SAVA: -113.40

Cassava Sciences's EBIT for the three months ended in Dec. 2023 was $-22.79 Mil.

Cassava Sciences EBIT per Share Historical Data

The historical data trend for Cassava Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences EBIT per Share Chart

Cassava Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.29

-0.26

-0.83

-1.99

-2.53

Cassava Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.51	-0.64	-0.69	-0.66	-0.54

Cassava Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cassava Sciences's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-105.957	/	41.932
=	-2.53

Cassava Sciences's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-22.789	/	42.193
=	-0.54

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.53

Cassava Sciences (NAS:SAVA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cassava Sciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cassava Sciences (Cassava Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

SAVA:Mexico PX91:Germany PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.

Executives

Sanford Robertson	director	ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook	officer: SVP & General Counsel	6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
James William Kupiec	officer: Chief Clinical Dev. Officer	7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen	officer: Chief Financial Officer	7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Remi Barbier	director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J	director
Robert Z Gussin	director
Scannon Patrick J Md Phd	director	C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann	director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p.	10 percent owner	405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174